Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients
Safety Issues
About this trial
This is an interventional treatment trial for Safety Issues focused on measuring MSC, AMI, PCI
Eligibility Criteria
Inclusion Criteria: Patents, with age ≤20 or ≤80 years old. Fit to the definition of ST-elevation myocardial infarction (anterior myocardial infarction): Chest pain onset. 12-lead EKG:V1-V6 ≥ consecutive lead ST-segment elevation ≥1 mm. TnT-I elevation. Into emergency ≤ 6h upon AMI presentation. Patients are willing to receive the treatment and sign the informed consent. Exclusion Criteria: Age < 20 or >80 years old. History of Malignancy. Sepsis (abnormal WBC count elevation). Hematologic disorder. AIDS. Advanced liver cirrhosis. CKD stage 5 with Ccr <15 ml/min. AMI occurrence > 6 hours Non-first AMI. Pregnancy or breastfeeding. Prison. Cancer treatment within 2 years. Expected lifespan < 6 months. Non-suitable candidate evaluated by PI. Participating in other clinical trials.
Sites / Locations
- Kaohsiung Chang Gung Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Low dose allogeneic mesenchymal stromal cells
High dose allogeneic mesenchymal stromal cells
Intracoronary administration 1.5 x 10^7 OmniMSC-AMI in first AMI patients who just underwent primary PCI
Intracoronary administration 3.0 x 10^7 OmniMSC-AMI in first AMI who just underwent primary PCI